tbuckley/cabot-search huggingface dataset:
Recent Trends in the Identification and Treatment of High Blood Cholesterol by Physicians
Authors: Wayne H. Giles
Journal: JAMA (1993)

<h3>Objective.</h3> —To investigate recent trends in the percentage and characteristics of patients being treated by a physician for high blood cholesterol (HBC) and to assess missed clinical opportunities to screen for HBC. <h3>Design, Setting, Participants.</h3> —Telephone interviews of 154735 adults in 37 states that participated in the Behavioral Risk Factor Surveillance System during 1988-1990 to assess trends in the percentage of patients treated for HBC by a physician. An opportunity was considered missed if a person did not report being screened for HBC despite seeing a physician for preventive care in the last 2 years. <h3>Results.</h3> —Between the first quarter of 1988 and the last quarter of 1990, the percentage of persons treated by a physician for HBC increased from 7.6% to 11.7% (<i>P</i>&lt;.001). However, since an estimated 36% of US adults need treatment for HBC, fewer than one third of persons who need treatment are receiving it. Persons with two or more cardiac risk factors were more likely to be treated, while men, blacks, persons in lower socioeconomic groups, and persons between 20 and 34 years of age were less likely to be treated. Among the 126571 persons who had seen a physician for preventive care within the last 2 years, missed opportunities to screen for HBC were most common among persons aged 20 through 34 years (59%) and among women who had seen obstetricians/gynecologists for preventive care (43%). <h3>Conclusions.</h3> —Fewer than one third of persons who need treatment for HBC as estimated by data from the second National Health and Nutrition and Nutrition Examination Survey are receiving treatment. Better use of clinical opportunities to screen for HBC could substantially accelerate the progress in identifying persons, young adults in particular, who are likely to benefit from cholesterol reduction. (<i>JAMA</i>. 1993;269:1133-1138)
Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Suzanne Trudel, Darrell White, Martin Gyger, Jonahtan Kaufmann, Andrzej Jakubowiak, Engin Gul, Lisa W Le, Zhihua Li, Donna Reece, Vishal Kukreti, Richard LeBlanc
Journal: Blood (2015)
Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor
Authors: Young Eun Lee, Seung Ah Choi, Pil Ae Kwack, Hak Jae Kim, Il Han Kim, Kyu-Chang Wang, Ji Hoon Phi, Ji Yeoun Lee, Sangjoon Chong, Sung-Hye Park, Kyung Duk Park, Do Won Hwang, Kyeung Min Joo, Seung-Ki Kim
Journal: Neuro-Oncology (2016)

Atypical teratoid/rhabdoid tumor (AT/RT) is one of the most common malignant brain tumors in infants. Although cancer stem cells of AT/RT express aldehyde dehydrogenase (ALDH), effective chemotherapies against AT/RT have not been established. Here, we examined radiosensitizing effects of disulfiram (DSF), an irreversible inhibitor of ALDH against AT/RT for a novel therapeutic method.Patient-derived primary cultured AT/RT cells (SNU.AT/RT-5 and SNU.AT/RT-6) and established AT/RT cell lines (BT-12 and BT-16) were used to assess therapeutic effects of combining DSF with radiation treatment (RT). Survival fraction by clonogenic assay, protein expression, immunofluorescence, and autophagy analysis were evaluated in vitro. Antitumor effects of combining DSF with RT were verified by bioluminescence imaging, tumor volume, and survival analysis in vivo.The results demonstrated that DSF at low concentration enhanced the radiosensitivity of AT/RT cells with reduction of survival fraction to 1.21‒1.58. DSF increased DNA double-strand break (γ-H2AX, p-DNA-PKcs, and p-ATM), apoptosis (cleaved caspase-3), autophagy (LC3B), and cell cycle arrest (p21) in irradiated AT/RT cells, while it decreased anti-apoptosis (nuclear factor-kappaB, Survivin, and B-cell lymphoma 2 [Bcl2]). In vivo, DSF and RT combined treatment significantly reduced tumor volumes and prolonged the survival of AT/RT mouse models compared with single treatments. The combined treatment also increased γ-H2AX, cleaved caspase-3, and LC3B expression and decreased ALDH1, Survivin, and Bcl2 expression in vivo.DSF and RT combination therapy has additive therapeutic effects on AT/RT by potentiating programmed cell death, including apoptosis and autophagy of AT/RT cells. We suggest that DSF can be applied as a radiosensitizer in AT/RT treatment.
Survival in triple-negative breast cancer (TNBC): Evidence from the SEER database 2010-2011.
Authors: Rebecca Alexandra Dent, Paul N. Mainwaring, Tira Jing Ying Tan, Sylvaine Barbier, Javier Cortes, Kimberly L. Blackwell, Shaheenah S. Dawood
Journal: Journal of Clinical Oncology (2015)

e12075 Background: Precision medicine has led to the definition of molecular phenotypes, such as TNBC.TNBC is characterized by a more aggressive biology and worst clinical outcome, stage for stage compared to other molecular phenotypes. Increasing use of second, third generation and drug specific combination chemotherapy regimens in TNBC as well as targeted therapies has emerged. We have interrogated the SEER database to look for survival outcomes in TNBC in light of these changes in patterns of care. Methods: Using the SEER database, we have looked at overall survival in over 10,000 women with TNBC according to stage. Tumors were coded as IHC ER, PR and HER2 negative. These women were diagnosed in 2010-2011 with subsequent follow up & should reflect current clinical practice (Sparano JCO 2015). Results: Demographics of these women: 20% Afro-Caribbean, 7% Asian and 72% Caucasian. 22% of women were born overseas. Pathology: G1-12%, G2 - 16%, G3 -77%; rest unknown. Stage at presentation; I 34%, II 42%, III 15% IV 6%, rest unknown. Surgery: 47% lumpectomy, 43% mastectomy, 9% no surgery. Overall survival by stage at 24 months; I 97%, II 93%, III 71%, IV 27%. Breast cancer specific survival by stage at 24 months: I 97%, II 95%, III 76%, IV 31%. See Graph 1. Conclusions: Our review demonstrated an overall survival of over 90% in early stage (I & II) TNBC at 2 years. Survival in more advanced stages remains short with medians of 12-14 months for MBC, which is in line with results from recent clinical trials (O'Shaughnessy JCO 2014, Tutt et al. SABCS 2014). The early separation of survival curves with advanced disease drives continued efforts to define subgroups for more precise therapeutic options.
PREDICTORS AND CLINICAL SIGNIFICANCE OF HIGH-SENSITIVITY CARDIAC TROPONIN-I ELEVATION AFTER DIAGNOSTIC CORONARY ANGIOGRAPHY
Authors: Rikuta Hamaya, Taishi Yonetsu, Tadashi Murai, Yoshihisa Kanaji, Eisuke Usui, Masahiro Hoshino, Takayuki Niida, Masahiro Hada, Sadamitsu Ichijo, Yoshinori Kanno, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2017)
Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients &gt; 70 years of age with previously untreated advanced non-small cell lung carcinoma
Authors: B. E. Johnson, J. Lucca, M. S. Rabin, T. J. Lynch, P. Ostler, A. T. Skarin, J. Temel, G. Liu, P. A. Janne
Journal: Journal of Clinical Oncology (2004)

7080 Background: Chemotherapy for patients ≥ 70 years of age with advanced NSCLC can be associated with greater toxicities than in younger patients. The identification of an efficacious therapy with minimal systemic toxicity would be particularly beneficial to elderly subjects. Erlotinib (Tarceva™) has shown promising activity, and a tolerable side effect profile, in the treatment of patients who have failed prior chemotherapy. We thus chose to conduct a single center phase II trial of erlotinib in patients ≥ 70 with previously untreated advanced NSCLC. Methods: Patients: chemotherapy naïve, IIIB (w/malignant effusion)/IV, PS 0–2; treated with erlotinib, 150 mg p.o. q.d., until evidence of disease progression or toxicity. Primary endpoint: median survival; secondary endpoints: response rate, quality of life (using LCSS), changes in FDG-PET, and analysis of EGFR signaling pathway from pre-treatment tumor specimens. Results: From 3/03 to 12/03, 36 pts were treated; 30 evaluable for toxicity and response; 1 for toxicity only; 5 too early. M/F: 19/17; median age 76 (70–86); PS 0/1/2:6/28/2; Path: adeno, 56%; squamous 14%; adeno w/BAC features, 11%; BAC, 11%; NSCLC unclassified 11%, large cell, 2%. Smoking: current/former/never: 2/30/4. Toxicity: rash 77%(grade 1/2: 92%, grade 3: 8%, grade 4:0%), diarrhea 61% (grade 1/2: 100%, grade3/4:0%). Other ≥ grade 3 toxicities: pneumonitis 2/31 (6.5%) and lacrimation 1/31 (3.2%). One patient died from drug toxicity (pneumonitis); 3/31 (9.6%) were dose reduced; 2/31 (6.5%) discontinued. Response: CR:0; PR: 4 (13.3%; 95% CI 5 - 29%); SD: 14 (46.6%; 95% CI 31–64%); PD:12 (40%). Median duration of response and stable disease: 6.8 (range 3.5–7.5+) and 3.5 months (range 1.5–8.0+), respectively. Survival and FDG-PET imaging are too early to evaluate. Conclusions: Erlotinib appears to be well tolerated and demonstrates encouraging activity in patients ≥ 70 years of age with previously untreated advanced NSCLC. Accrual is continuing to 60 patients and updated response, survival and FDG-PET data will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech
SAFETY AND OUTCOMES OF CATHETER ABLATION FOR TREATMENT OF REFRACTORY VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH ADVANCED HEART FAILURE
Authors: Michael Cowherd, Peter Rothstein, Alexis Tumolo, Natasha Altman, Prateeti Khazanie, Amrut Ambardekar, Andreas Brieke, Eugene Wolfel, William Cornwell, Matthew Zipse, Duy Nguyen, Lucas Marzec, Ryan Aleong, Christine Tompkins, Larry Allen, William Sauer, Wendy Tzou
Journal: Journal of the American College of Cardiology (2017)
A phase I-II trial of docetaxel and daily thalidomide in patients with previously treated recurrent non-small cell lung cancer
Authors: C. W. Seidler, J. Rooney, D. Kodali, S. Khanani, W. Walsh, J. Gordon
Journal: Journal of Clinical Oncology (2004)

7281 Background: To Evaluate the effectiveness and toxicity of oral thalidomide combined with docetaxel as second-line therapy for progressive NSCLC. Methods: Eligibility criteria included recurrent/progressive NSCLC, prior chemotherapy, measurable/evaluable disease, PS 0–2 and adequate hematologic, renal and hepatic function. Pts with hypercoagulable state, uncontrolled CNS disease were excluded. Docetaxel 75mg/m2 was administered every 3 weeks (maximum of 8 cycles) with thalidomide 50mg orally daily escalated by 50 mg every 3 weeks to a maximum dose of 200mg day and continued until disease progression or dose limiting toxicity. All pts received warfarin 2mg daily or continued on usual anticoagulant therapy for thromboembolism prophylaxis. Primary endpoints are survival (OS), time to disease progression (TTP), and response rate (RECIST criteria). Results: To date 14 patients are enrolled, 13 were eligible for treatment. 12 received sufficient treatment for evaluation of disease progression, 14 were evaluable for survival. For evaluable pts: Mean PS = 1, median age 64.5 years, mean number of prior chemtherapy regimens = 1.2. Response rate was 14.2 % (1CR,1PR). Stable disease was reported in 3 pts (21.3%). Estimate of median TTP by Kaplan Meyer method is 11.5 (95%CI 4.4–16.7) weeks: median OS 3.4(95%CI 1.8, not reached) months. Grade 3/4 neutropenia was observed in 7/12 (58%). One episode of febrile neutropenia requiring hospitalization was observed. One episode of pulmonary embolism was seen. No neuropathy greater than grade 1 was reported. Other grade 1/2 toxicities included fatigue, constipation, and alopecia. To date no significant additional toxicity was seen with the addition of thalidomide to docetaxel. A total accrual of 35 is planned. Conclusions: These data suggest thalidomde in doses of 200 mg/day can be safely combined with docetaxel 75mg/m2 every 3 weeks in the treatment of NSCLC. The response rates and TTP, while preliminary, compare favorably with previously reported studies with docetaxel in this population. A larger confirmatory trial is in progress. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis
Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
Authors: Douglas G. McNeel, Daniel W. Lin, Thomas Gardner, Nadeem A. Sheikh, James Boyd Whitmore, Robert Brownell Sims, Robert Dreicer
Journal: Journal of Clinical Oncology (2012)

4650 Background: Sipuleucel-T is the first autologous cellular immunotherapy approved for asymptomatic or minimally symptomatic mCRPC. In the IMPACT trial, pts treated with sipuleucel-T had transient increases in eosinophil counts compared with control. In this retrospective analysis, we assess potential correlations between eosinophilia, overall survival (OS), prostate cancer-specific survival (PCSS) and immune response following sipuleucel-T. Methods: Data from three phase III trials (D9901, D9902A, and IMPACT) were pooled. The analysis included CBCs performed at baseline and wks 2–34. Eosinophilia was defined as either &gt;ULN (with normal baseline), or a max change from baseline within the top quartile, at any time between wks 2–16. Results: Increased eosinophil counts were seen in sipuleucel-T pts by wk 6, decreasing to near baseline by wk 14; eosinophil counts in control pts were stable. Of 377 sipuleucel-T pts eligible for analysis, 105 (27.9%) had eosinophilia. Baseline disease characteristics associated with eosinophilia were indicative of better prognosis (i.e., longer Halabi predicted survival [p=0.007], lower PSA [P=0.033], higher Hgb [p&lt;0.001], and no prior docetaxel [p=0.012]). In univariate analyses, eosinophilia correlated with improved OS (HR=0.75; 95%CI: 0.56–1.01; p=0.057) and PCSS (HR=0.71; 95%CI: 0.53–0.97; p=0.031); trends persisted after adjusting for Halabi. The magnitude of eosinophilia positively correlated with antigen-specific humoral responses (p ≤0.039 for wks 6, 14 and 26) and elevations in the cytokines at wk 6 (IL2 [p=0.011], IL5 [p=0.038] and TARC [p=0.001]). AEs occurring more frequently (p&lt;0.05) in pts with eosinophilia were infusion-related: pyrexia (33.3 v 21.3%) and nausea (19.0 v 10.7%). No cases of hypereosinophilic syndrome were reported. Conclusions: Increases in eosinophils after sipuleucel-T correlated with improved OS and PCSS. Large increases in eosinophil counts were associated with humoral responses and Th2-type cytokine production. Further studies of eosinophilia as a biomarker for sipuleucel-T response, particularly in earlier disease settings, are of interest.
RIGHT VENTRICLE FREE WALL STRAIN PREDICTS POST-SURGICAL LOW CARDIAC OUTPUT SYNDROME IN PATIENTS UNDERGOING AORTIC VALVE REPLACEMENT
Authors: Karla Balderas, Hugo Rodriguez Zanella, Juan Francisco Fritche-Salazar, Antonio Jordan-Rios, Nydia Avila Vanzzini, Luis Eduardo Juarez-Orozco, Jose Antonio Arias-Godinez, Eduardo Bucio-Reta, Oscar Calvillo Argüelles, Beatriz Dominguez, Manuel Gaxiola, Marco Martinez-Rios
Journal: Journal of the American College of Cardiology (2017)
WEEKEND VERSUS WEEKDAY PRESENTATION FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: FINDINGS FROM A UNITED STATES NATIONWIDE ANALYSIS
Authors: Pedro Arturo Villablanca, Tanush Gupta, Sahil Agrawal, Sahil Khera, Dhaval Kolte, David Briceno, Mark Menegus, Robert Pyo, Jose Wiley, Anna Bortnick, David Slovut, Ernest Monrad, Gregg Fonarow, Deepak Bhatt, Mario Garcia
Journal: Journal of the American College of Cardiology (2017)
TIME IN THERAPEUTIC RANGE PREDICTS MORTALITY AND CEREBROVASCULAR EVENTS IN ATRIAL FIBRILLATION PATIENTS TREATED WITH WARFARIN
Authors: Malini Madhavan, Suraj Kapa, Veronique Roger, Susan Weston, Jill M. Killian, Samuel Asirvatham, Bernard Gersh, Alanna Chamberlain
Journal: Journal of the American College of Cardiology (2017)
Preclinical Development of a T-Cell ALL CAR Demonstrates That Differences in CAR Membrane Distribution May Impact Efficacy
Authors: Haneen Shalabi, Haiying Qin, Kelsey Wanhainen, Jillian Smith, Rimas Orentas, Nirali N Shah, Shannon L Maude, Sarah K Tasian, David T Teachey, Javed Khan, Terry J Fry
Journal: Blood (2016)
LONG FOLLOW-UP OF PATIENTS WITH STRUCTURAL HEART DISEASE AND SYNCOPE: DOES THE SYNCOPE CAUSE MATTERS?
Authors: Jose Plutarco Gutierrez Yanez, Tiago Luiz Luz Leiria, Raphael Boesche Guimaraes, Gustavo Glotz De Lima, Maico Furlanetto, Matias Galeazzi Farina
Journal: Journal of the American College of Cardiology (2017)
Longitudinal comparison of body mass index (BMI) in breast cancer survivors to cancer-free women: A prospective study in high-risk women.
Authors: Amy L Gross, Sarah A Davidovics, Jennifer E Axilbund, Deborah Kay Armstrong, Betty J May, Kala Visvanathan
Journal: Journal of Clinical Oncology (2013)

1601 Background: Postdiagnosis weight gain in non-familial breast cancer (BC) survivors has been observed in a number of studies, with the reported prevalence and amount of weight gain being highly variable. Most studies did not include a cancer-free comparison group. Change in BMI has not been studied in BC survivors from high-risk populations. Methods: In an ongoing prospective cohort of women at Johns Hopkins with a family history of BC, ovarian cancer, and/or a BRCA1/2 mutation, we identified 249 survivors of stage 0-III BC and 400 cancer-free women who completed a baseline and at least one follow-up questionnaire and were age &gt; 30 years (yrs) at enrollment. Linear regression was used to estimate % change in self-reported BMI from baseline to follow-up (median 3.7 yrs) for survivors compared to cancer-free women including the effects of time between BC diagnosis and baseline, and differing BC treatment. Results: Mean age at baseline was 54.6 yrs among for survivors and 50.2 yrs among for cancer-free women. Mean age at BC diagnosis was 48.7 yrs with &gt; 50% diagnosed under 50 yrs, and 23% with ER- tumors. Baseline BMI did not differ between survivors and cancer-free women irrespective of tumor subtype. However, the average change in BMI was 1.79% (95% CI 0.32, 3.26) greater in survivors compared to cancer-free women in models adjusted for age, baseline BMI, menopausal status, physical activity, enrollment yr, and bilateral oophorectomy. The increase in BMI was highest (β = 4.22%; 95% CI 1.74, 6.70) in survivors diagnosed within 1 yr of baseline. Change in BMI in survivors diagnosed &gt; 5 yrs prior to baseline did not significantly differ from cancer-free women. A significantly greater increase in BMI was also observed in survivors diagnosed at age &gt; 50 yrs, and in those who received chemotherapy and not hormone therapy. Conclusions: In this study of BC survivors and cancer-free women enrolled from the same source population, we observed a greater percent increase in BMI over time among survivors, particularly those diagnosed within 5 yrs of baseline and/or treated with chemotherapy. Survivors in these categories may benefit from interventions aimed to reduce weight gain post diagnosis.
MORTALITY EFFECT OF ICD IN PRIMARY PREVENTION OF NON ISCHEMIC CARDIOMYOPATHY: A META ANALYSIS OF RANDOMIZED CONTROL TRIALS
Authors: Hemindermeet Singh, Ameer Kabour, Abdur Khan, Sonia Ali Malik, Owais Khawaja, Haris Riaz, Wade Lee, Mark Richards, Johan Aasbo, Faraz khan Luni
Journal: Journal of the American College of Cardiology (2017)
포스터발표 : 컨벤션홀 특설 발표장 ; 정상 혈청 알파태아단백 수치를 보이는 간세포암의 임상걱, 병리학적 특징
Authors: 우현영, 윤승규, 권정현, 김진동, 김창욱, 최종영, 배시현, 한준열, 양진모, 이영석, 이창돈
Journal: Clinical and Molecular Hepatology (2008)
Abolished Daily Expression Patterns of SIRT1, SIRT2, and SIRT5 in Human Chronic Myeloid Leukemia
Authors: Ming-Yu Yang, Pai-Mei Lin, Jui-Feng Hsu, Wen-Chi Yang, Yi-Chang Liu, Hui-Hua Hsiao, Chao-Sung Chang, Cheng-Ming Hsu, Sheng-Fung Lin
Journal: Blood (2012)
PREVALENCE AND CLINICAL SIGNIFICANCE OF LIPID-RICH PLAQUE DETECTED BY OPTICAL COHERENCE TOMOGRAPHY: A FOUR-YEAR FOLLOW-UP STUDY
Authors: Lei Xing, Takumi Higuma, Zhao Wang, Aaron Aguirre, Shaosong Zhang, Bo Yu, Hang Lee, James Fujimoto, Valentin Fuster, Ik-Kyung Jang
Journal: Journal of the American College of Cardiology (2017)
Actively controlled release of Dexamethasone from neural microelectrodes in a chronic in vivo study
Authors: C. Boehler, C. Kleber, N. Martini, Y. Xie, I. Dryg, T. Stieglitz, U.G. Hofmann, M. Asplund
Journal: Biomaterials (2017)

Stable interconnection to neurons in vivo over long time-periods is critical for the success of future advanced neuroelectronic applications. The inevitable foreign body reaction towards implanted materials challenges the stability and an active intervention strategy would be desirable to treat inflammation locally. Here, we investigate whether controlled release of the anti-inflammatory drug Dexamethasone from flexible neural microelectrodes in the rat hippocampus has an impact on probe-tissue integration over 12 weeks of implantation. The drug was stored in a conducting polymer coating (PEDOT/Dex), selectively deposited on the electrode sites of neural probes, and released on weekly basis by applying a cyclic voltammetry signal in three electrode configuration in fully awake animals. Dex-functionalized probes provided stable recordings and impedance characteristics over the entire chronic study. Histological evaluation after 12 weeks of implantation revealed an overall low degree of inflammation around all flexible probes whereas electrodes exposed to active drug release protocols did have neurons closer to the electrode sites compared to controls. The combination of flexible probe technology with anti-inflammatory coatings accordingly offers a promising approach for enabling long-term stable neural interfaces.
IMPACT OF MODERATE MITRAL REGURGITATION ON PATIENTS: MORTALITY MAY BE UNDERESTIMATED – ANALYSIS OF CLINICAL DATA REPOSITORIES
Authors: Irmina Gradus-Pizlo, Abhishek Khemka, Richard Kovacs, Wanzhu Tu, Ross Hayden, Abdullah Masud, George Eckert, William Tierney
Journal: Journal of the American College of Cardiology (2017)